The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. This evidence concerns the gene CD5 and lymphoplasmacytic lymphoma.